AMPAC Fine Chemicals Expands Petersburg, Virginia, Operations Center
05/10/2021
According to city officials, AMPAC Fine Chemicals is a major collaborator in the new U.S. government-funded partnership with Phlow Corporation, Medicines for All Institute, and non-profit drugmaker Civica Inc. Through this partnership, Phlow executed a $354 million contract with the U.S. Biomedical Advanced Research and Development Authority to produce essential medications using advanced manufacturing processes from the Medicines for All Institute based at the College of Engineering at Virginia Commonwealth University.
“Of our three AMPAC locations, Virginia offers an enabling environment for developing and sustaining the growth in capacity and infrastructure demanded for the pharmaceutical industry,” said Dr. William DuBay, AMPAC Global Vice President of Research and Development. “Our growing relationship with the Commonwealth, VEDP, the City of Petersburg, and others, including VCU, Phlow, and Civica, is a cornerstone of our vision for American-based manufacturing of critical pharmaceutical ingredients.”
As an incentive, Virginia Economic Development Partnership (VEDP) worked with the City of Petersburg, Virginia’s Gateway Region, the Community College Workforce Alliance and Dominion Energy to secure the project for the Commonwealth. Governor Northam approved a $640,000 grant from the Commonwealth’s Opportunity Fund to assist the City of Petersburg with the project. The Governor also approved a $250,000 Virginia Investment Performance Grant, a performance-based incentive that encourages continued capital investment by existing Virginia companies. The company is eligible to receive benefits from the Major Business Facility Job Tax Credit for new, full-time jobs created.
“This major expansion boosts the fast-growing pharmaceutical manufacturing campus in Petersburg and is a major win for the region and the Commonwealth,” said Secretary of Commerce and Trade Brian Ball. “We are confident Virginia’s workforce training programs and skilled talent pipeline will ensure AMPAC’s continued success, and applaud the company and its partners for fulfilling the mission to provide quality products to patients everywhere.”
As part of this initiative, city officials said AFC will expand the former Boehringer Ingelheim chemical plant, purchased in 2016, and in operation since 2019. In January, Governor Northam announced that Civica Inc. would invest $124.5 million to establish a new facility adjacent to Phlow’s future operation and AMPAC’s existing facility. The Civica plant will convert active pharmaceutical ingredients from AMPAC and Phlow into vials and syringes of finished medications for use in hospitals.
“Our region is emerging as a pharmaceutical manufacturing cluster and we look forward to supporting AMPAC and its partner companies as they stabilize America’s essential medicine supply chain,” added Keith Boswell, President and CEO of Virginia’s Gateway Region Economic Development Organization added.
Project Announcements
ValorFlex Packaging Plans Bowling Green, Kentucky, Production Operations
06/30/2025
Neuro.io Plans Terrebonne Parish, Louisiana, Operations
06/30/2025
Germany-Based MTU Maintenance Expands Fort Worth, Texas, MRO Operations
06/30/2025
Cascade Die Casting Group Expands High Point, North Carolina, Manufacturing Operations
06/30/2025
BuildOps Plans Raleigh, North Carolina, Operations
06/30/2025
Point Blank Enterprises Plans Wakulla County, Florida, Operations
06/30/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024